A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma

Published:2016-02-08 Issue:4 Volume:57 Page:880-887
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Luminari Stefano,Goldaniga Maria,Cesaretti Marina,Orsucci Lorella,Tucci Alessandra,Pulsoni Alessandro,Salvi Flavia,Arcaini Luca,Carella Angelo Michele,Tedeschi Alessandra,Pinto Antonello,Stelitano Caterina,Baldini Luca

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1091934

Reference23 articles.

1. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases

2. Epidemiology, pathology and treatment of non-follicular indolent lymphomas

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment;eClinicalMedicine;2024-06

2. Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience;Supportive Care in Cancer;2021-02-06

3. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma;BLOOD;2020

4. Follicular lymphoma: first - line selection criteria of treatment;Terapevticheskii arkhiv;2019-08-15

5. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe);Clinical Cancer Research;2019-06-26